Cognito Therapeutics raised $105M to push Spectris, its at‑home light‑and‑sound therapy for Alzheimer’s, closer to an FDA filing as pivotal trial data arrive.

After 15 years, Dr. Kevin Tabb will step down from Beth Israel Lahey Health within a year as the system launches a national search and readies a Dana‑Farber cancer hospital.

Five Boston‑area companies landed on LexisNexis’ Top 100 Global Innovators list — the region’s strongest showing yet across biotech and consumer tech.

Ginkgo Bioworks is pivoting from benches to sell AI‑powered lab robots and a cloud lab out of its Boston Seaport hub after years of losses. The company hopes automation will revive revenue.

ARPA‑H is directing new program money into Boston’s Investor Catalyst Hub — backing lymphatic therapies and tear‑based monitoring — even as state leaders press for clarity after a stop‑work notice.

Watertown‑based Disc Medicine cut about 20% of its staff after the FDA issued a Complete Response Letter for bitopertin; the company says a Phase 3 readout now dictates next steps.

Logan Airport has rolled out TSA PreCheck Touchless ID in three terminals, letting opted-in PreCheck flyers verify identity with a facial scan while privacy questions linger.

Boston startups raised about $922M in February and added two unicorns, led by AI, fintech and cybersecurity rounds that kept local venture activity hot.

A Penn–Harvard team embedded an ultrathin electronic mesh into pancreatic organoids, boosting cell maturity and glucose responsiveness.

Mass General Brigham teams pair gene research with a validated Brain Care Score that studies link to sizable reductions in dementia risk.

Novo Nordisk partnered with Boston startup Vivtex to develop next‑generation oral obesity and diabetes pills. The deal could deliver up to $2.1 billion to the local biotech.

Massachusetts plans to join the GUARDIAN newborn genome‑screening pilot that tests for 450+ treatable genetic conditions. The voluntary program would require state review before enrollment begins.

Klaviyo co-founders Ed Hallen and Andrew Bialecki pledged $6 million to MIT’s delta v accelerator, boosting per-team funding and mentorship to help keep startups in Boston.